drugset / Trial / NCT01221246
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Phase 2
Completed
34 enrolled
Genervon Biopharmaceuticals, LLC
California Pacific Medical Center Research Institute · collabColumbia University · collabHoag Memorial Hospital Presbyterian · collabHuntington Hospital · collabSarasota Memorial Hospital · collabUniversity Hospital Erlangen · collabUniversity of California, Los Angeles · collabUniversity of Louisville · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more of the blood vessels supplying the brain) when administered up to 18 hours after symptoms begin.
Timeline
- Start
- 2011-03-08
- Primary completion
- 2016-07-07
- Completion
- 2016-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM602 | Unknown | 320 mg | Intravenous |
| Subject | GM602 | Unknown | 480 mg | Intravenous |